Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mohieddin Jafari has a total of 392 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Conjunctive Targeting Links Drug Synergy to Emergent Proteome Structural States

    by Guoqing Cheng, Rabah Soliymani, Elham Gholizadeh, Pouya Behrouzi, Mahdi Muhaddesi, Risto Renkonen, Markku Varjosalo, Amir A. Saei, Mohieddin Jafari

    Combinatorial therapies are widely used in the treatment of acute myeloid leukemia (AML) to address disease heterogeneity, adaptive resistance, and rewired signaling and metabolic states. Yet drug prioritization remains largely guided by clinical or phenotypic evidence, while the molecular mechanisms underlying effective drug combinations remain incompletely defined. To narrow this gap, we developed Combinatorial high-ratio Partial proteolysis with reference PRoteome Analysis (CoPPRA), a structural proteomics workflow based on limited proteolysis of cell lysates that profiles drug-associated changes in regional protein accessibility at peptide-level resolution. Here, we applied CoPPRA to ruxolitinib and ulixertinib, individually and in combination, in AML-related cell lysates. Our findings extend conjunctive targeting (CT), a recently proposed mechanism of combinatorial drug action in which combined exposure produces protein targeting patterns not observed with either drug alone. Previously identified through combination-associated changes in protein solubility/stability, CT is examined here at peptide-level resolution through regional differences in proteolytic accessibility. The ruxolitinib–ulixertinib combination produced broad peptide-level accessibility changes, including a subset meeting the predefined criteria for CT. CT candidates predominantly exhibited regional accessibility changes, with altered peptide regions occurring against comparatively small changes across the remaining quantified peptides from the same proteins. MAP2K1 and ATP6V1G1 showed pronounced differences between overlapping peptide sequences, highlighting localized variation in combination-associated accessibility, including an ATP6V1G1 peptide mapping to an annotated helical region. Combination-associated increases in peptide signals were also observed in PIK3R1, BRD4, and PTPN11, linking regional accessibility changes to signaling and transcriptional regulators relevant to AML. Functional enrichment and network analyses further implicated nucleotide and glucose metabolism, ficolin-1-rich granules, ribosome-associated processes, and phagocytic vesicles. These results extend conjunctive targeting from protein-level solubility/stability changes to regional differences in proteolytic accessibility, showing that combination-associated effects can be concentrated within specific peptide regions rather than distributed uniformly across proteins. More broadly, CoPPRA provides a peptide-resolved approach for investigating the molecular features of combinatorial drug action and prioritizing protein regions for subsequent mechanistic validation.

  • Open Access

    Chemical Proteomics of Residual Acute Myeloid Leukemia Cells Reveals Therapeutic Vulnerabilities

    by Elham Gholizadeh, Uladzislau Vadadokhau, Mücahit Varli, Danilo Ritz, Komal Kumar Javarappa, Mika Kontro, Blassan George, Raphael Itzykson, Markku Varjosalo, Risto Renkonen, et al.

    Venetoclax combined with azacitidine has improved treatment outcomes in acute myeloid leukemia (AML), yet relapse and treatment persistence remain major clinical challenges. To investigate proteomic mechanisms associated with venetoclax–azacitidine response and adaptation, we applied a multi-layer combinatorial proteome integral solubility/stability alteration analysis (CoPISA) strategy in SKM-1 AML cells. Cells were treated with venetoclax, azacitidine, their combination, or vehicle control and profiled across four orthogonal layers: short-term lysate CoPISA, short-term intact-cell CoPISA, long-term intact-cell CoPISA after 5 days of treatment, and long-term expression proteomics of surviving cells. The venetoclax–azacitidine combination induced treatment-specific protein solubility and abundance changes that were not fully reproduced by either single agent. Long-term surviving cells displayed extensive proteomic remodeling, consistent with the emergence of an adaptive drug-tolerant state, although contributions from pre-existing resilient cell populations cannot be excluded. Integration of short- and long-term solubility changes with abundance remodeling revealed distinct adaptive regimes, including retained biochemical targets, dosage-compensated targets, sensitive-state-specific targets, and remodeled adaptive targets. This framework prioritized candidate resistance-associated proteins, including NRP2, RPL18, PLP2, RPS28, and NOTCH1. NRP2 emerged as a top candidate across all proteomics layers, consistently showing increased abundance. Overall, this study shows that combining CoPISA with expression proteomics can resolve temporally distinct proteomic states of venetoclax–azacitidine response and identify candidate adaptive vulnerabilities in AML.

  • Open Access

    Deep proteomics profiling of the cell secretome by DeepSec

    by Amir Ata Saei, Xueyao Wang, Konstantinos Fragkoulis, Aleksandra Wielento, Sabine Willems, Marie-Stéphanie Aschtgen, Anna Kirk, Seyed Majed Modaresi, Hassan Gharibi, Mohieddin Jafari, et al.

    Cellular secretome profiling is essential for decoding intercellular communication, identifying disease biomarkers, and discovering therapeutic targets. Although mass spectrometry-based proteomics is the gold standard for discovery-driven analysis, deep secretome profiling remains technically challenging because low-abundance signaling molecules are masked by the vast dynamic range of high-background serum supplements. To overcome these limitations, we develop DeepSec, a robust and streamlined method that uses a small-molecule–modulated nanoparticle protein corona to selectively deplete bovine serum albumin from conditioned media. Using an endogenous lipopolysaccharide (LPS) dose-response series, DeepSec preserved biological fold changes relative to a non-depleted workflow and orthogonal ELISA, establishing protein-corona enrichment as a quantitatively faithful strategy for dynamic secretome proteomics. In parallel, DeepSec increased the number of significantly secreted proteins by three-fold. We demonstrate its utility for profiling secretomes from cultured cells and host–pathogen interaction models. Using pathway-specific inhibitors, we further resolve proteins secreted through ER–Golgi- and autophagy-dependent routes following LPS stimulation. Finally, we show the translational utility of DeepSec by profiling patient-derived 3D liver microtissues modeling metabolic dysfunction-associated steatohepatitis, capturing distinct, drug-specific metabolic and extracellular matrix rewiring patterns in response to clinical therapeutics. These results establish DeepSec as a robust platform for interrogating complex extracellular signaling networks across diverse models of health and disease.

  • Open Access

    A dataset supporting Combinatorial Proteome Integral Solubility/Stability Alteration Analysis (CoPISA)

    by Ehsan Zangene, Elham Gholizadeh, Uladzislau Vadadokhau, Danilo Ritz, Amir A. Saei, Mohieddin Jafari

    Combination therapies are widely used in acute myeloid leukemia (AML), but systematic datasets capturing proteome-wide responses to multi-drug perturbations remain limited. Here we present CoPISA (Combinatorial Proteome Integral Solubility/Stability Alteration), a quantitative proteomics assay designed to profile protein solubility and stability responses to single and combined drug treatments. The dataset includes two AML drug pairs (LY3009120–sapanisertib and ruxolitinib–ulixertinib) applied to four AML cell lines (MOLM-13, MOLM-16, SKM-1, and NOMO-1) under control, single-agent, and combination conditions in both lysate and intact-cell formats. Thermal solubility profiling coupled with TMT-based multiplexed LC–MS/MS generated 16 TMT16-plex experiments comprising 192 LC–MS/MS raw files, providing deep proteome coverage across treatments and biological contexts. The resource includes raw and processed proteomics data, detailed experimental metadata in Sample and Data Relationship Format (SDRF), and reproducible analysis scripts for reporter normalization, protein-level aggregation, statistical modeling, and classification of combinatorial response patterns. The experimental design enables identification of proteins responding uniquely to combination treatments as well as overlapping single-agent effects. Technical validation demonstrates reproducible quantification across multiplex experiments and assay formats. All data are publicly available through the PRIDE repository (PXD066812) together with analysis code, enabling independent reanalysis and method development. This dataset provides a benchmark resource for studying proteome responses to drug combinations, comparing lysate and intact-cell perturbation profiles, developing computational approaches for combinatorial target inference, and supporting training in computational proteomics.


  • Open Access

    DORSSAA: Drug-Target interactOmics Resource Based on Stability/Solubility Alteration Assay

    by Ehsan Zangene, Elham Gholizadeh, Veit Schwämmle, Amir Ata Saei, Mathias Wilhelm, Lukas Käll, Mohieddin Jafari


  • Open Access

    Solubility based mechanistic profiling of combinatorial drug therapy

    by Elham Gholizadeh, Ehsan Zangene, Uladzislau Vadadokhau, Danilo Ritz, Juho J. Miettinen, Rabah Soliymani, Marc Baumann, Mathias Wilhelm, Esko Kankuri, Paul A. Haynes, et al.

    Acute myeloid leukemia (AML) remains challenging to treat due to extensive genetic heterogeneity, high relapse rates, and treatment-related toxicity. Although drug combinations offer therapeutic promise, their selection is often empirical. Here, we introduce Combinatorial Proteome Integral Solubility/Stability Alteration analysis (CoPISA), a high-throughput proteomics workflow that captures protein solubility/stability alterations uniquely induced by drug combinations. We applied CoPISA to two rationally designed AML drug pairs, LY3009120-sapanisertib (LS) and ruxolitinib-ulixertinib (RU), previously identified as the most effective and least toxic combinations among many candidates and validated in AML cell lines, patient-derived samples and zebrafish xenograft models. We uncovered an emergent mechanism termed “conjunctional targeting”, in which combinatorial drug action induces combination-exclusive protein targets consistent with an AND-gate logic model. LS-specific converged on SUMOylation, chromatin condensation, and VEGF-linked adhesion, while RU-specific targets disrupted DNA-damage checkpoints, mitochondrial bioenergetics, and RNA-splicing. Post-translational modification analysis revealed combination-induced acetylation, methylation, and phosphorylation of key AML proteins, including NPM1. Network analysis demonstrated that a substantial fraction of AML-associated proteins targeted by CoPISA are unique to combinations, including DNMT3A, NPM1, and TP53. By uncovering a mechanistic layer beyond classical synergy, CoPISA provides a robust framework for the precision-guided design of combinatorial therapies in heterogeneous cancers.


  • Open Access

    CoPISA: Combinatorial Proteome Integral Solubility/Stability Alteration analysis

    by Ehsan Zangene, Elham Gholizadeh, Uladzislau Vadadokhau, Danilo Ritz, Amir A. Saei, Mohieddin Jafari

    Combination therapies are widely used in acute myeloid leukemia (AML), but systematic datasets capturing proteome-wide responses to multi-drug perturbations remain limited. Here we present CoPISA (Combinatorial Proteome Integral Solubility/Stability Alteration), a quantitative proteomics assay designed to profile protein solubility and stability responses to single and combined drug treatments. The dataset includes two AML drug pairs (LY3009120–sapanisertib and ruxolitinib–ulixertinib) applied to four AML cell lines (MOLM-13, MOLM-16, SKM-1, and NOMO-1) under control, single-agent, and combination conditions in both lysate and intact-cell formats. Thermal solubility profiling coupled with TMT-based multiplexed LC–MS/MS generated 16 TMT16-plex experiments comprising 192 LC–MS/MS raw files, providing deep proteome coverage across treatments and biological contexts. The resource includes raw and processed proteomics data, detailed experimental metadata in Sample and Data Relationship Format (SDRF), and reproducible analysis scripts for reporter normalization, protein-level aggregation, statistical modeling, and classification of combinatorial response patterns. The experimental design enables identification of proteins responding uniquely to combination treatments as well as overlapping single-agent effects. Technical validation demonstrates reproducible quantification across multiplex experiments and assay formats. All data are publicly available through the PRIDE repository (PXD066812) together with analysis code, enabling independent reanalysis and method development. This dataset provides a benchmark resource for studying proteome responses to drug combinations, comparing lysate and intact-cell perturbation profiles, developing computational approaches for combinatorial target inference, and supporting training in computational proteomics.

  • Open Access

    Boolean logic links chromatin accessibility states to gene expression variability across cell types

    by Seyed Amir Malekpour, Mohieddin Jafari, Mehdi Sadeghi

    Multiomic technologies have enabled simultaneous profiling of chromatin accessibility and gene expression, providing a rich foundation for decoding cis-regulatory logic. However, existing approaches emphasize pairwise correlations and overlook the combinatorial, multilocus accessibility states that govern gene regulation in a context-specific manner. We present ocrRBBR, a computational framework that infers interpretable Boolean rules from combinations of accessible open chromatin regions (OCRs) to explain gene expression variability across diverse cell types. These rules [e.g. $(\lnot OCR_A \wedge OCR_B)\ \text{or}\ (OCR_A \wedge OCR_B)$] capture regulatory logic ranging from synergistic to additive (redundant) enhancer interactions, revealing how OCR combinations drive cell-type-specific gene expression. Applying ocrRBBR to paired ATAC–RNA data, we uncover thousands of Boolean rules linked to both lineage-restricted and broadly expressed genes. We show that cell-type-specific genes rely on fewer but more selective Boolean rules that integrate signals from a larger number of OCRs, including distal enhancers. In contrast, housekeeping genes depend on more numerous, simpler rules that involve fewer OCRs, reflecting a modular and additive regulatory logic. Functional enrichment analysis reveals that genes regulated by cell-type-specific rules are enriched for lineage-defining pathways. Together, ocrRBBR offers a mechanistically interpretable and biologically grounded framework for decoding combinatorial cis-regulatory logic from multimodal genomic data.

  • Open Access

    Informative Missingness in Nominal Data: A Graph-Theoretic Approach to Revealing Hidden Structure

    by Ehsan Zangene, Veit Schwämmle, Mohieddin Jafari

    Missing data is often treated as a nuisance, routinely imputed or excluded from statistical analyses, especially in nominal datasets where its structure cannot be easily modeled. However, the form of missingness itself can reveal hidden relationships, substructures, and biological or operational constraints within a dataset. In this study, we present a graph-theoretic approach that reinterprets missing values not as gaps to be filled, but as informative signals. By representing nominal variables as nodes and encoding observed or missing associations as edges, we construct both weighted and unweighted bipartite graphs to analyze modularity, nestedness, and projection-based similarities. This framework enables downstream clustering and structural characterization of nominal data based on the topology of observed and missing associations; edge prediction via multiple imputation strategies is included as an optional downstream analysis to evaluate how well inferred values preserve the structure identified in the nonmissing data. Across a series of biological, ecological, and social case studies, including proteomics data, the BeatAML drug screening dataset, ecological pollination networks, and human resource analytics, we demonstrate that the structure of missing values can be highly informative. These configurations often reflect meaningful constraints and latent substructures, providing signals that help distinguish between data missing at random and not at random. When analyzed with appropriate graph-based tools, these patterns can be leveraged to improve the structural understanding of data and provide complementary signals for downstream tasks such as clustering and similarity analysis. Our findings support a conceptual shift: Missing values are not merely analytical obstacles but valuable sources of insight that, when properly modeled, can enrich our understanding of complex systems across domains.


  • Open Access

    Preventing Proteomics Data Tombs Through Collective Responsibility and Community Engagement

    by Uladzislau Vadadokhau, Mai Soliman, Leticia Castillon, Paula Pastor Muñoz, Linda Id, Swethaa Natraj Gayathri, Ankita Srivastava, Tyko Runeberg, Tamara González-Armijos, Karina Šapovalovaitė, et al.

    Public proteomics repositories now host vast amounts of mass spectrometry data, yet much of it remains difficult to reuse, risking “data tombs” that are open access but not practically re-analyzable. In spring 2025, a graduate-level course at the University of Helsinki tasked six student teams with reanalyzing six projects from the Proteomics Identification Database (label-free quantification only) using a common R-based workflow (rpx, mzR, QFeatures, DEP/MSqRob2/limma/OmicsQ packages) that was shared across all teams. The teams reproduced identification, optional quantification, normalization, imputation, and differential expression analyses, and compared the outcomes to the original studies. As expected, systemic barriers recurred across cases: (i) no sample and data relationship format for proteomics metadata in any of the cases; (ii) missing details regarding decoy sets for false discovery rate assessment; (iii) proprietary-only outputs or software (e.g., Thermo.msf, Progenesis) that impeded open reanalysis in interoperable, community-standard formats; (iv) missing data-independent acquisition spectral libraries or protein sequences database files (FASTA); (v) absent or vague normalization/imputation/statistical parameters; (vi) inconsistent file naming; and (vii) insufficient biological/technical replication in at least one project. These shortcomings yielded large discrepancies in the analysis results (e.g., 13,068 vs. 4,923 proteins; 108 vs. 11 differentially expressed proteins), and, in one instance, a highlighted protein lacked robust support in the deposited identifications. We observed that reproducibility in mass spectrometry-based proteomics hinges less on instruments than on transparent metadata, open formats, and executable analysis provenance. We propose that data creators provide a minimum re-analysis package, including raw data and open formats, community standards, basic quality control summaries, data-independent acquisition spectral libraries, and complete parameter/code sets with pinned versions or containers. Moreover, we recommend repository-level nudges toward making such packages mandatory. This educational exercise simultaneously trains the students as well as stress-tests the community data practices to prevent proteomics “data tombs”.